Trial · NCT05934110
Registered outcomes35
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
21 to 35 of 35
Download this page as JSON| List | Outcome | Time frame | Description |
|---|---|---|---|
| Secondary | Absolute change from baseline in fasting high-density lipoprotein (HDL) | Baseline and week 26 | Efficacy endpoints |
| Secondary | Absolute change from baseline in fasting low-density lipoprotein (LDL) | Baseline and week 26 | Efficacy endpoints |
| Secondary | Absolute change from baseline in fasting triglycerides (TGs) | Baseline and week 26 | Efficacy endpoints |
| Secondary | Absolute change from baseline in fasting Apolipoprotein A1 (ApoA1) | Baseline and week 26 | Efficacy endpoints |
| Secondary | Absolute change from baseline in fasting Apolipoprotein B (ApoB) | Baseline and week 26 | Efficacy endpoints |
| Secondary | Absolute change from baseline in fasting high sensitivity C-reacting protein (hs-CRP) | Baseline and week 26 | Efficacy endpoints |
| Secondary | Absolute change from baseline in fasting albumin | Baseline and week 26 | Efficacy endpoints |
| Secondary | Absolute change from baseline in homeostatic model assessment (HOMA) index | Baseline and week 26 | Efficacy endpoints |
| Secondary | Absolute change from baseline in Visceral adiposity index (VAI) | Baseline and week 26 | Efficacy endpoints VAI Males = (WC/(39.38+(1.88\*BMI)))\*(TG/1.03)\*(1.31/HDL) VAI Females = (WC/(36.58+(1.89\*BMI)))\*(TG/0.81)\*(1.52/HDL) |
| Secondary | Absolute change from baseline in Fatty liver index (FLI) | Baseline and week 26 | Efficacy endpoints. Measured as FLI = 100\*e to the power of y /(1+e to the power of y) y= 0.953\*ln(TG)+0,139\*BMI+0.718\*ln(GGT)+0.053\*WC-15.3745 |
| Secondary | Absolute change from baseline in systolic and diastolic blood pressure | Baseline and week 26 | Efficacy endpoints |
| Secondary | Absolute change from baseline in heart rate | Baseline and week 26 | Efficacy endpoints |
| Secondary | Tolerability, assessed by conventional adverse event (AE) reporting (with special focus on oily spotting and fecal incontinence) | IMP administration until the end-of-study visit. Assessed at all nine visits (both outpatient and telephone visits) | Safety \& tolerability endpoints |
| Secondary | Number of withdrawals from study (total and gastrointestinal [GI] related) | Visit 1 until the end-of-study visit. Assessed at all nine visits (both outpatient and telephone visits) | Safety \& tolerability endpoints |
| Secondary | Absolute change from baseline in fasting liver enzymes | Baseline and week 26 | Safety \& tolerability endpoints (aspartate aminotransferase, alanine aminotransferase, alkaline phosphatase and gamma-glutamyl transferase) |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT05934110/registered?page=2